Patients who received CAR-T cell therapy survived for an average of 7.9 months, compared to 5.5 months with standard care. They also experienced 3.3 months without their cancer progressing, versus 1.8 months.

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if the cancer is detected after the cancer cells have migrated, that number drops to 31%.

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

A cocktail of FDA-approved cancer drugs, trametinib and rapamycin, boosts the lifespan of lab mice by 30% and might help humans age better, new study finds.

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study presented at an ASCO meeting.

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in patients with PD-L1-positive locally advanced unresectable or metastatic triple-negative breast cancer (TNBC).

Her son missed school for cancer treatment. Now that he’s in remission, the letter writer worries she’s too involved in managing his anxieties at school.

According to this meta-analysis, exercise therapy (specifically mind-body modalities like yoga and tai chi) were found to significantly reduce anxiety and depression in older cancer patients, thus improving their health-related quality of life.

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global healthcare budgets.